Vaxcyte (PCVX) 10-K2024 FY Annual report

Filed: 25 Feb 25, 4:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: AEs, allergic, Allergy, alongside, appealed, Asia, assay, Attorney, Becerra, biotech, BMl, born, Braidwood, Bright, BTD, CapvaxiveTM, Carlo, Carolina, certiorari, Chapel, Chicago, Chlamydia, chosen, Circuit, CMMI, Contextual, controversial, dance, depletion, deployment, disband, downsize, ectopic, ETASU, female, flawed, floor, forestall, Furey, gave, grew, Hampshire, Hill, Hirth, imaging, Imvax, Indiana, infertility, Iowa, Jersey, job, John, Kentucky, lawsuit, Loper, male, membership, Moderna, Montana, Monte, nationwide, NIAID, nil, notable, obese, Oregon, outage, overturned, panel, peer, Peter, Pickering, predecessor, pregnancy, protectionist, PSU, Raimondo, repatriate, representation, reproductive, rest, round, sexually, shareholder, simulation, sixty, skeptical, skin, struck, subcaption, sublease, subleasee, sublessor, sublet, subsidized, SVP, Tennessee, treatable, trillion, TSR, unified, unremitted, urgently, Washington, white, XpressCFTM

Removed: accommodate, Aid, aimed, Alto, averaged, bargain, belief, bidding, CAGR, charitable, clarifying, clearance, clinician, compatible, compensatory, concordance, confirmed, contemplated, convey, deduct, deducted, demonstration, differential, directing, downgraded, dual, epidemiological, Finally, fluctuated, forgiven, Foster, fulfill, furlough, furniture, immunogenically, Industrial, instructed, investor, lapsing, leased, leveraged, loan, mandating, modular, moved, Nonmonetary, oAdvance, oLeverage, oncology, oOur, outsourced, package, Palo, Paycheck, percent, PPP, presidential, productivity, progressing, prolonged, rational, recognizing, reconsider, reexamining, relocation, reserve, restaurant, retained, revisited, Road, roughly, shut, shutdown, simplified, substitution, tenant, Trump, twelve, unamortized, unconjugated, unnecessary, Vaxneuvance, vote, waiting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PCVX transcripts

PCVX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Grant E. Pickering, Chief Executive Officer of Vaxcyte, Inc. (the “Company”), and Andrew Guggenhime, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

1.The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 25, 2025

/s/ Grant E. Pickering /s/ Andrew Guggenhime

Grant E. Pickering Andrew Guggenhime

Chief Executive Officer President and Chief Financial Officer

“This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Vaxcyte, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.”